Light Science Technologies Holdings PLC (AIM:LST) said it has agreed to acquire the trade and assets of Injecta Fire Barrier (IFB) under a deferred profit share agreement, with no initial or fixed outlay, from chief executive Simon Deacon.
This means the acquisition is expected to be quickly cash-generative and to be self-funding for the group "from day one".
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has received a patent grant from the Japanese Patent Office for its Immunomodulator II.
This patent covers the pharmaceutical composition of POLB 001, designed for treating severe influenza in hospitalised patients in combination with antiviral compounds. The formal issuance of the granted patent is anticipated soon.